185 related articles for article (PubMed ID: 37838724)
21. Role of Flavonoids in the Prevention of AhR-Dependent Resistance During Treatment with BRAF Inhibitors.
Leclair HM; Tardif N; Paris A; Galibert MD; Corre S
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708687
[TBL] [Abstract][Full Text] [Related]
22. Plasma proteome alterations by MAPK inhibitors in BRAF
Babačić H; Eriksson H; Pernemalm M
Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells.
Misek SA; Newbury PA; Chekalin E; Paithankar S; Doseff AI; Chen B; Gallo KA; Neubig RR
Mol Pharmacol; 2022 Jan; 101(1):1-12. PubMed ID: 34732527
[TBL] [Abstract][Full Text] [Related]
24. Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma.
Dar AA; Bezrookove V; Nosrati M; Ice R; Patino JM; Vaquero EM; Parrett B; Leong SP; Kim KB; Debs RJ; Soroceanu L; Miller JR; Desprez PY; Cleaver JE; Salomonis N; McAllister S; Kashani-Sabet M
Proc Natl Acad Sci U S A; 2022 Aug; 119(34):e2206824119. PubMed ID: 35969744
[TBL] [Abstract][Full Text] [Related]
25. BRAF Inhibitors Amplify the Proapoptotic Activity of MEK Inhibitors by Inducing ER Stress in NRAS-Mutant Melanoma.
Niessner H; Sinnberg T; Kosnopfel C; Smalley KSM; Beck D; Praetorius C; Mai M; Beissert S; Kulms D; Schaller M; Garbe C; Flaherty KT; Westphal D; Wanke I; Meier F
Clin Cancer Res; 2017 Oct; 23(20):6203-6214. PubMed ID: 28724666
[No Abstract] [Full Text] [Related]
26. Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.
Muraro E; Montico B; Lum B; Colizzi F; Giurato G; Salvati A; Guerrieri R; Rizzo A; Comaro E; Canzonieri V; Anichini A; Del Vecchio M; Mortarini R; Milione M; Weisz A; Pizzichetta MA; Simpson F; Dolcetti R; Fratta E; Sigalotti L
Front Immunol; 2024; 15():1336566. PubMed ID: 38510242
[TBL] [Abstract][Full Text] [Related]
27. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
Dugo M; Nicolini G; Tragni G; Bersani I; Tomassetti A; Colonna V; Del Vecchio M; De Braud F; Canevari S; Anichini A; Sensi M
Oncotarget; 2015 Mar; 6(7):5118-33. PubMed ID: 25742786
[TBL] [Abstract][Full Text] [Related]
28. Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
Hao X; Falo Iii LD; Chen G; Zhang J; Carey CD; Storkus WJ; Falo LD; You Z
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408093
[TBL] [Abstract][Full Text] [Related]
29. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
Jandova J; Wondrak GT
J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
[TBL] [Abstract][Full Text] [Related]
30. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
[TBL] [Abstract][Full Text] [Related]
31. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma.
Cybulska-Stopa B; Rogala P; Czarnecka AM; Galus Ł; Dziura R; Rajczykowski M; Kubiatowski T; Wiśniewska M; Gęga-Czarnota A; Teterycz P; Ziobro M; Suwiński R; Mackiewicz J; Rutkowski P
Melanoma Res; 2020 Oct; 30(5):465-471. PubMed ID: 32221131
[TBL] [Abstract][Full Text] [Related]
32. TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors.
Oliveira ÉA; Chauhan J; Silva JRD; Carvalho LADC; Dias D; Carvalho DG; Watanabe LRM; Rebecca VW; Mills G; Lu Y; da Silva ASF; Consolaro MEL; Herlyn M; Possik PA; Goding CR; Maria-Engler SS
Pharmacol Res; 2021 Nov; 173():105911. PubMed ID: 34560251
[TBL] [Abstract][Full Text] [Related]
33. Targeting of PDGF-C/NRP-1 autocrine loop as a new strategy for counteracting the invasiveness of melanoma resistant to braf inhibitors.
Ruffini F; Ceci C; Atzori MG; Caporali S; Levati L; Bonmassar L; Cappellini GCA; D'Atri S; Graziani G; Lacal PM
Pharmacol Res; 2023 Jun; 192():106782. PubMed ID: 37127213
[TBL] [Abstract][Full Text] [Related]
34. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
35. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction.
Moriceau G; Hugo W; Hong A; Shi H; Kong X; Yu CC; Koya RC; Samatar AA; Khanlou N; Braun J; Ruchalski K; Seifert H; Larkin J; Dahlman KB; Johnson DB; Algazi A; Sosman JA; Ribas A; Lo RS
Cancer Cell; 2015 Feb; 27(2):240-56. PubMed ID: 25600339
[TBL] [Abstract][Full Text] [Related]
36. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
[TBL] [Abstract][Full Text] [Related]
37. Should Targeted Therapy Be Continued in BRAF-Mutant Melanoma Patients after Complete Remission?
Bédouelle E; Nguyen JM; Varey E; Khammari A; Dreno B
Dermatology; 2022; 238(3):517-526. PubMed ID: 34818219
[TBL] [Abstract][Full Text] [Related]
38. Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
Fratangelo F; Camerlingo R; Carriero MV; Pirozzi G; Palmieri G; Gentilcore G; Ragone C; Minopoli M; Ascierto PA; Motti ML
Int J Oncol; 2018 Sep; 53(3):1149-1159. PubMed ID: 29956724
[TBL] [Abstract][Full Text] [Related]
39. Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway.
Gupta R; Bugide S; Wang B; Green MR; Johnson DB; Wajapeyee N
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4583-4591. PubMed ID: 30782837
[TBL] [Abstract][Full Text] [Related]
40. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
Shen CH; Kim SH; Trousil S; Frederick DT; Piris A; Yuan P; Cai L; Gu L; Li M; Lee JH; Mitra D; Fisher DE; Sullivan RJ; Flaherty KT; Zheng B
Nat Med; 2016 Sep; 22(9):1056-61. PubMed ID: 27500726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
